Biologics Safety Testing Market: Growth, Size, Share, and Trends
Biologics Safety Testing Market by Product (Kits, Reagents, Instruments), Services, Test Type (Mycoplasma, Sterility, Endotoxin, Bioburden), Product & Services by Application (Vaccines, mAbs, CGT), End User, Competition, Region - Global Forecast to 2031
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global biologics safety testing market is projected to reach USD 9.66 billion by 2031, up from USD 5.57 billion in 2026, at a CAGR of 11.6%. Biologics safety testing comprises analytical products and services used to detect microbial contamination, endotoxins, mycoplasma, viruses, and process-related impurities, ensuring the safety, quality, and regulatory compliance of biologic products. The market includes assays, kits and reagents, instruments, and specialized testing services that support biologics development, manufacturing, and batch release across monoclonal antibodies, vaccines, cell and gene therapies, blood products, and other biologics.
KEY TAKEAWAYS
-
BY REGIONNorth America accounted for the largest market share, by region, in 2025: 43%.
-
BY OFFERINGBy offering, in 2025, the product segment had the largest share of 41.9%.
-
BY END USERPharmaceutical & biotechnology companies dominated the biologics safety testing products market in 2025 with a share of 56.0%.
-
COMPETITIVE LANDSCAPE - Key PlayersThermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Charles River Laboratories (US) were identified as some of the star players in the global biologics safety testing market, given their strong market share and product and service footprint.
-
COMPETITIVE LANDSCAPE - StartupsClean Biologics (France), PathoQuest (France), ARL Bio Pharma, Inc.(US), have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The global biologics safety testing market is expanding steadily, driven by the growing development of biologics, increasing regulatory focus on product safety, and rising demand for advanced testing solutions across development and manufacturing.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The biologics safety testing market is advancing steadily, driven by innovations in rapid microbiological methods, analytical technologies, automation, and evolving regulatory standards aligned with increasingly complex biologics development. The growing global demand for monoclonal antibodies, vaccines, biosimilars, and advanced therapies is accelerating the need for sensitive, reliable safety testing solutions. Expanding use of advanced assays, automated platforms, and specialized testing services is supporting more efficient detection of microbial contamination, endotoxins, mycoplasma, viruses, and process-related impurities. Scalable and validated testing technologies are gaining wider adoption, improving quality control, supporting regulatory compliance, and aligning with evolving manufacturing and quality expectations across major biopharmaceutical markets.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Rising Biologics and Biosimilars Pipeline

-
Stringent and Evolving Regulatory Requirements
Level
-
High Cost of Advanced Testing Equipment and Limited Specialized Expertise
-
Regulatory Divergence Across Regions
Level
-
Growing focus on next-generation therapeutics
-
Shift Toward Animal-Free Testing Approaches
Level
-
Assay Standardization Gap
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Rising Biologics and Biosimilars Pipeline
The expanding biologics and biosimilars pipeline is driving demand for safety testing, as these products require rigorous validation at each development stage. Increasing approvals and complex modalities are accelerating the adoption of advanced assays to ensure quality, compliance, and faster commercialization timelines.
Restraint: High Cost of Advanced Testing Equipment and Limited Specialized Expertise
High costs of advanced biologics safety testing equipment and limited skilled expertise hinder market growth. Technologies such as rapid microbial detection and molecular assays require significant investment and technical capabilities, thereby restricting adoption among smaller biotech firms and emerging players, especially in developing regions.
Opportunity: Growing focus on next-generation therapeutics
The shift toward next-generation therapeutics, including cell and gene therapies, creates strong opportunities for biologics safety testing. These complex products require highly sensitive methods, driving innovation and increasing demand for specialized testing solutions to ensure safety, efficacy, and regulatory compliance globally.
Challenge: Assay Standardization Gap
Lack of assay standardization across biologics safety testing creates major challenges. Differences in protocols, validation requirements, and regulatory expectations lead to inconsistencies, complicating global development and approvals, while increasing costs, timelines, and operational complexity for manufacturers operating across multiple regions and product types.
BIOLOGICS SAFETY TESTING MARKET: GROWTH, SIZE, SHARE, AND TRENDS: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Utilizes endotoxin detection kits, rapid sterility testing, and mycoplasma detection solutions to ensure the safety of biologics, including cell and gene therapies, across raw materials, in-process samples, and final products | Enables highly sensitive detection of contaminants such as endotoxins and mycoplasma, reducing batch failure risks, improving product quality, and supporting regulatory compliance through faster and more reliable safety testing workflows |
|
|
Provides comprehensive biologics safety testing, including endotoxin (LAL-based) assays, mycoplasma detection, sterility, and viral safety testing across raw materials, in-process samples, and final biologic products, supporting cell and gene therapy manufacturing and regulatory submissions | Enables rapid, highly sensitive contamination detection with reduced turnaround times, improving product release efficiency, ensuring global regulatory compliance, and minimizing the risk of batch failure through robust, end-to-end safety testing strategies. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The global biologics safety testing market is a highly interconnected ecosystem in which biopharmaceutical companies, biotechnology firms, and research institutions collaborate to ensure the safety and quality of complex biologics. Testing service providers and technology companies offer advanced solutions for endotoxin detection, sterility testing, mycoplasma screening, and viral safety. Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) support testing across development and manufacturing stages. Regulatory authorities and healthcare systems across regions such as North America and Europe establish stringent guidelines, driving compliance and ensuring safe commercialization of biologics.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Global Biologics Safety Testing Market, by Offerings
In 2025, services dominated the biologics safety testing market due to increasing outsourcing to CROs and CDMOs, rising complexity of biologics, and the need for specialized expertise, driving higher adoption of end-to-end testing solutions across development and manufacturing stages.
Global Biologics Safety Testing Market, by Product
Assays, kits, and reagents held a significant share in 2025, driven by their widespread use in routine safety testing, including endotoxin, mycoplasma, and sterility testing, and by their ease of use, rapid results, and compatibility with standardized laboratory workflows.
Global Biologics Safety Testing Market, by Test Type
Residual host cell protein and DNA detection tests accounted for a major share in 2025, owing to stringent regulatory requirements for impurity testing and their critical role in ensuring product purity and safety in biologics manufacturing.
Global Biologics Saftey Testing Product Market, by Application
Monoclonal antibodies and therapeutic proteins dominated in 2025 due to their large pipeline, increasing approvals, and extensive safety testing requirements across all stages of development and commercial production.
Global Biologics Safety Testing Service Market, by Applications
Vaccine safety testing held a highest share in 2025, supported by ongoing global immunization programs, increased vaccine development, and stringent regulatory requirements for batch release and quality assurance.
GlobalBiologics Safety Testing Product Market, by Product End Users
In 2025, pharmaceutical & biotechnology companies accounted for the largest share among product end users, driven by high biologics production, in-house testing needs, and continuous demand for quality control and regulatory compliance.
Global Biologics Safety Testing Service Market, by Service End Users
Pharmaceutical & biotechnology companies also led in service end users in 2025, as they increasingly outsource complex safety testing to specialized providers to reduce costs, improve efficiency, and accelerate time-to-market.
REGION
Asia Pacific to be fastest-growing region in market during forecast period
During the forecast period, the Asia Pacific is expected to emerge as a fast-growing region in the global biologics safety testing market, driven by expanding biopharmaceutical manufacturing, increasing investments in biotechnology, and improving regulatory frameworks. Rising adoption of biologics, including biosimilars and vaccines, along with growing clinical trial activity, is boosting demand for safety testing. Additionally, the presence of cost-effective CROs and CDMOs, coupled with increasing outsourcing by global companies and advancements in testing capabilities, is further accelerating regional market growth.

BIOLOGICS SAFETY TESTING MARKET: GROWTH, SIZE, SHARE, AND TRENDS: COMPANY EVALUATION MATRIX
In the global biologics safety testing market, Thermo Fisher Scientific is the star player, driven by its diverse portfolio of testing instruments, assay kits, and integrated services spanning endotoxin, sterility, and microbial detection. The company continues to lead through technological innovation, broad global reach, and strong partnerships with biopharma companies and CDMOs. Samsung Biologics is an emerging leader, with its expanding biologics manufacturing capabilities and integrated quality and safety testing services. Its focus on end-to-end bioprocessing support, advanced analytics, and strategic collaborations positions it strongly to capture growing demand for outsourced biologics safety testing.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Thermo Fisher Scientific Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Charles River Laboratories (US)
- Laboratory Corporation of America Holdings (US)
- Merck KGaA (Germany)
- Lonza (Switzerland)
- Fujifilm Corporation (Japan)
- BIOMERIEUX(France)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 4.97 Billion |
| Market Forecast in 2031 (Value) | USD 9.66 Billion |
| Growth Rate | CAGR of 11.6% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
WHAT IS IN IT FOR YOU: BIOLOGICS SAFETY TESTING MARKET: GROWTH, SIZE, SHARE, AND TRENDS REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Evaluate competitive positioning of key players in the biologics safety testing market | Analyzed portfolios of leading biologics safety testing providers across sterility testing, endotoxin testing, mycoplasma testing, virus safety testing, bioburden testing, and residual impurity testing; benchmarked players by service breadth, product depth, technology capabilities, geographic reach, and end-user focus | Supports strategic decision-making by identifying competitive white spaces, capability gaps, partnership targets, and differentiation opportunities |
| Assess high-growth testing segments and technology opportunities | Evaluated demand across major test categories, rapid microbiology methods, PCR/qPCR, NGS-based viral safety, recombinant endotoxin reagents, and automation-linked QC workflows | Helps prioritize the most attractive growth pockets, investment themes, and innovation areas in the biologics safety testing market |
RECENT DEVELOPMENTS
- December 2025 : Thermo Fisher Scientific Inc. expanded its Bioprocess Design Centers in Asia to strengthen support for biologics, vaccines, and cell and gene therapy development and manufacturing.
- January 2026 : Charles River Laboratories, Inc. acquired PathoQuest SAS to strengthen its biologics testing business with rapid, in vitro NGS-based viral safety, biopharmaceutical characterization, and product release testing capabilities.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
- 5.1 INTRODUCTION
-
5.2 MARKET DYNAMICSDRIVERS- Development of mAbs and biosimilars- Growing concerns over cell culture contamination- Rising investments in biopharmaceutical R&D- Increasing demand for advanced therapy medicinal products (ATMPs)- Stringent regulatory requirements for biologics safety testingRESTRAINTS- Ethical concerns related to animal testingOPPORTUNITIES- Growth opportunities in emerging markets- Increasing outsourcing of biopharmaceutical activities to CROs- Rising focus on next-generation therapeuticsCHALLENGES- High cost of biologics- Challenges related to biologics complexity and heterogenicity
-
5.3 TECHNOLOGY ANALYSISKEY TECHNOLOGIES- Polymerase chain reaction (PCR)- Next-generation sequencing (NGS)COMPLEMENTARY TECHNOLOGIES- Lab-on-a-chip (LOC) systems- High-content screening (HCS)ADJACENT TECHNOLOGIES- Bioinformatics and computational biology
- 5.4 SUPPLY CHAIN ANALYSIS
- 5.5 VALUE CHAIN ANALYSIS
- 5.6 PRICING ANALYSIS
-
5.7 ECOSYSTEM ANALYSISRAW MATERIAL VENDORS IN BIOLOGICS SAFETY TESTING MARKETPRODUCT VENDORS IN BIOLOGICS SAFETY TESTING MARKETSERVICE PROVIDERS IN BIOLOGICS SAFETY TESTING MARKETEND USERS IN BIOLOGICS SAFETY TESTING MARKETREGULATORY BODIES GOVERNING BIOLOGICS SAFETY TESTING MARKET
-
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
-
5.9 PATENT ANALYSISMETHODOLOGYPATENTS FILED, BY DOCUMENT TYPE, 2014–2024INNOVATION AND PATENT APPLICATIONSTOP APPLICANTS
- 5.10 KEY CONFERENCES & EVENTS
-
5.11 REGULATORY LANDSCAPEINTRODUCTIONREGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONSREGULATORY SCENARIO
-
5.12 PORTER’S FIVE FORCES ANALYSISTHREAT OF NEW ENTRANTSTHREAT OF SUBSTITUTESBARGAINING POWER OF SUPPLIERSBARGAINING POWER OF BUYERSINTENSITY OF COMPETITIVE RIVALRY
-
5.13 KEY STAKEHOLDERS & BUYING CRITERIAKEY STAKEHOLDERS IN BUYING PROCESSBUYING CRITERIA FOR BIOLOGICS SAFETY TESTING MARKET
- 5.14 INVESTMENT/FUNDING SCENARIO
- 6.1 INTRODUCTION
-
6.2 SERVICESMYCOPLASMA TESTING SERVICES- Increasing focus on development of biologics and biosimilars to support segmental growthSTERILITY TESTING SERVICES- Rising focus on development of biologics and biosimilars to drive demand for sterility testing servicesENDOTOXIN TESTING SERVICES- Stringent regulatory requirements to drive marketVIRUS SAFETY TESTING SERVICES- Rising focus on development of advanced therapies to drive growthBIOBURDEN TESTING SERVICES- Growing adoption of advanced testing solutions for contamination risk mitigation to propel growthOTHER BIOLOGICS SAFETY TESTING SERVICES
-
6.3 CONSUMABLESINCREASING DEMAND FOR HIGH-QUALITY ASSAYS AND REAGENTS TO DRIVE MARKET
-
6.4 INSTRUMENTSRISING ADOPTION OF ADVANCED TECHNOLOGIES TO SUPPORT MARKET GROWTH
- 7.1 INTRODUCTION
-
7.2 RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTSSTRINGENT REGULATORY GUIDELINES FOR BIOLOGIC DRUG MANUFACTURING TO PROPEL MARKET
-
7.3 MYCOPLASMA TESTSRISING CONCERNS OF CELL CULTURE CONTAMINATION TO DRIVE MARKET
-
7.4 STERILITY TESTSCOMPULSORY STERILITY TESTING AT EACH STAGE IN DRUG DEVELOPMENT AND PRODUCTION PROCESS TO SUPPORT SEGMENT GROWTH
-
7.5 ENDOTOXIN TESTSINCREASING RESEARCH AND DEVELOPMENT FOR PRODUCTION OF BIOLOGICS TO DRIVE MARKET
-
7.6 VIRUS SAFETY TESTSGROWING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE SEGMENT GROWTH
-
7.7 BIOBURDEN TESTSGROWING STRINGENCY OF DRUG SAFETY STANDARDS TO INCREASE DEMAND FOR MICROBIOLOGICAL BIOBURDEN TESTING
- 7.8 OTHER BIOLOGICS SAFETY TESTS
- 8.1 INTRODUCTION
-
8.2 MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURINGGROWING REGULATORY APPROVALS FOR MONOCLONAL ANTIBODIES TO SUPPORT MARKET GROWTH
-
8.3 VACCINES DEVELOPMENT AND MANUFACTURINGRISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE GROWTH
-
8.4 CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURINGINCREASING INVESTMENTS FOR DEVELOPMENT OF CELLULAR & GENE THERAPIES TO DRIVE GROWTH
-
8.5 BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURINGGROWING DEMAND FOR BLOOD PRODUCTS TO PROPEL GROWTH
- 8.6 OTHER APPLICATIONS
- 9.1 INTRODUCTION
-
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIESINCREASING PHARMACEUTICAL R&D SPENDING AND GROWING STRATEGIC ALLIANCES TO DRIVE GROWTH
-
9.3 CROS & CDMOSINCREASING FOCUS ON EXPANSION OF CROS AND CDMOS TO PROPEL GROWTH
-
9.4 ACADEMIC & RESEARCH INSTITUTESSURGE IN R&D ACTIVITIES FOR DEVELOPMENT OF ADVANCED THERAPIES TO BOOST MARKET GROWTH
- 10.1 INTRODUCTION
-
10.2 NORTH AMERICANORTH AMERICA: RECESSION IMPACTUS- Increasing investments in biotechnology industry to drive market growthCANADA- Investments for expanding biomanufacturing capacity to propel market growth
-
10.3 EUROPEEUROPE: RECESSION IMPACTGERMANY- Expansion initiatives by key market players to support market growthUK- Emphasis on vaccine manufacturing and biotech R&D to drive marketFRANCE- Rising focus on cell & gene therapy R&D to promote market growthITALY- Rising life sciences R&D and growing biotech industry to boost marketSPAIN- Growing expansion of biotech companies and increasing R&D expenditure to drive marketREST OF EUROPE
-
10.4 ASIA PACIFICASIA PACIFIC: RECESSION IMPACTCHINA- China to dominate APAC marketJAPAN- Growing government initiatives and expansion of biopharma companies to boost marketINDIA- Funding for biopharma sector and focus on cell-based therapies to propel market growthSOUTH KOREA- Growing focus on advancing bioprocessing sector to drive marketAUSTRALIA- Rising incidence of chronic diseases and booming life science sector to drive marketREST OF ASIA PACIFIC
-
10.5 LATIN AMERICALATIN AMERICA: RECESSION IMPACTBRAZIL- Brazil to hold largest share of LATAM marketMEXICO- Increasing government support for biopharmaceutical production to drive marketREST OF LATIN AMERICA
-
10.6 MIDDLE EASTMIDDLE EAST: RECESSION IMPACTGCC COUNTRIES- Saudi Arabia- United Arab Emirates- Rest of GCC countriesREST OF MIDDLE EAST
-
10.7 AFRICARISING PREVALENCE OF CHRONIC DISEASES AND INCREASING GRANTS & FUNDS FOR BIOPHARMA SECTOR TO FUEL MARKET GROWTHAFRICA: RECESSION IMPACT
- 11.1 INTRODUCTION
- 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 11.3 REVENUE ANALYSIS
- 11.4 MARKET SHARE ANALYSIS
- 11.5 BRAND/PRODUCT COMPARISON
-
11.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023STARSEMERGING LEADERSPERVASIVE PLAYERSPARTICIPANTSCOMPANY FOOTPRINT: KEY PLAYERS, 2023- Overall footprint- Product and service footprint- Regional footprint- Test type footprint- Application footprint
-
11.7 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023PROGRESSIVE COMPANIESRESPONSIVE COMPANIESDYNAMIC COMPANIESSTARTING BLOCKSCOMPETITIVE BENCHMARKING: START-UPS/SMES, 2023
- 11.8 VALUATION AND FINANCIAL METRICS
-
11.9 COMPETITIVE SCENARIOPRODUCT LAUNCHESDEALSEXPANSIONS
- 12.1 INTRODUCTION
-
12.2 KEY PLAYERSTHERMO FISHER SCIENTIFIC INC.- Business overview- Products/Services/Solutions offered- Recent developments- MnM viewCHARLES RIVER LABORATORIES- Business overview- Products/Services/Solutions offered- Recent developments- MnM viewLABORATORY CORPORATION OF AMERICA HOLDINGS- Business overview- Products/Services/Solutions offered- Recent developments- MnM viewF. HOFFMANN-LA ROCHE LTD.- Business overview- Products/Services/Solutions offered- MnM viewMERCK KGAA- Business overview- Products/Services/Solutions offered- Recent developments- MnM viewSARTORIUS AG- Business overview- Products/Services/Solutions offeredLONZA- Business overview- Products/Services/Solutions offered- Recent developmentsFUJIFILM CORPORATION- Business overview- Products/Services/Solutions offered- Recent developmentsBIOMÉRIEUX- Business overview- Products/Services/Solutions offeredMARAVAI LIFESCIENCES- Business overview- Products/Services/Solutions offered- Recent developmentsWUXI APPTEC- Business overview- Products/Services/Solutions offered- Recent developmentsSGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA.- Business overview- Products/Services/Solutions offered- Recent developmentsSOTERA HEALTH- Business overview- Products/Services/Solutions offered- Recent developmentsSAMSUNG BIOLOGICS- Business overview- Products/Services/Solutions offered- Recent developmentsGENSCRIPT- Business overview- Products/Services/Solutions offeredAGILENT TECHNOLOGIES, INC.- Business overview- Products/Services/Solutions offeredSYNGENE INTERNATIONAL LIMITED- Business overview- Products/Services/Solutions offered- Recent developmentsEUROFINS SCIENTIFIC- Business overview- Products/Services/Solutions offered- Recent developmentsBIO-RAD LABORATORIES, INC.- Business overview- Products/Services/Solutions offered- Recent developmentsQIAGEN- Business overview- Products/Services/Solutions offered- Recent developments
-
12.3 OTHER PLAYERSPROMEGA CORPORATIONCATALENT, INC.ASSOCIATES OF CAPE COD, INC.CLEAN BIOLOGICSPATHOQUESTPACIFIC BIOLABSARL BIO PHARMA, INC.FRONTAGE LABSCREATIVE BIOGENEADVAXIA BIOLOGICS
- 13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
- 13.2 CUSTOMIZATION OPTIONS
- 13.3 RELATED REPORTS
- 13.4 AUTHOR DETAILS
- TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
- TABLE 2 BIOLOGICS SAFETY TESTING MARKET: IMPACT ANALYSIS
- TABLE 3 LIST OF FDA-APPROVED BIOSIMILAR PRODUCTS, 2022–2024
- TABLE 4 PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2020 VS. 2026 (USD BILLION)
- TABLE 5 LIST OF APPROVED GENE THERAPIES, 2023–2024
- TABLE 6 PRICING OF ADVANCED THERAPIES
- TABLE 7 APPLICATIONS OF PCR IN BIOLOGICS SAFETY TESTING
- TABLE 8 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
- TABLE 9 AVERAGE SELLING PRICE OF BIOLOGICS SAFETY TESTING PRODUCTS, BY REGION
- TABLE 10 BIOLOGICS SAFETY TESTING MARKET: ROLE OF RAW MATERIAL VENDORS
- TABLE 11 BIOLOGICS SAFETY TESTING MARKET: ROLE OF PRODUCT VENDORS
- TABLE 12 BIOLOGICS SAFETY TESTING MARKET: ROLE OF SERVICE PROVIDERS
- TABLE 13 BIOLOGICS SAFETY TESTING MARKET: ROLE OF END USERS
- TABLE 14 BIOLOGICS SAFETY TESTING MARKET: ROLE OF REGULATORY BODIES
- TABLE 15 PATENTS FILED, 2014–2024
- TABLE 16 TOP 20 PATENT OWNERS IN BIOLOGICS SAFETY TESTING MARKET, 2014–2024
- TABLE 17 PATENTS IN BIOLOGICS SAFETY TESTING MARKET, 2024
- TABLE 18 BIOLOGICS SAFETY TESTING MARKET: KEY CONFERENCES & EVENTS, 2024–2025
- TABLE 19 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 20 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 21 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 22 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 23 BIOLOGICS SAFETY TESTING MARKET: REGULATORY GUIDELINES
- TABLE 24 BIOLOGICS SAFETY TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS
- TABLE 25 BUYING CRITERIA FOR BIOLOGICS SAFETY TESTING PRODUCTS & SERVICES, BY END USER
- TABLE 26 BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 27 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 28 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 29 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 30 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 31 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 32 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 33 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 34 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 35 MYCOPLASMA TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 36 NORTH AMERICA: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 37 EUROPE: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 38 ASIA PACIFIC: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 39 LATIN AMERICA: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 40 MIDDLE EAST: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 41 GCC COUNTRIES: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 42 STERILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 43 NORTH AMERICA: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 44 EUROPE: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 45 ASIA PACIFIC: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 46 LATIN AMERICA: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 47 MIDDLE EAST: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 48 GCC COUNTRIES: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 49 ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 50 NORTH AMERICA: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 51 EUROPE: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 52 ASIA PACIFIC: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 53 LATIN AMERICA: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 54 MIDDLE EAST: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 55 GCC COUNTRIES: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 56 VIRUS SAFETY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 57 NORTH AMERICA: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 58 EUROPE: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 59 ASIA PACIFIC: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 60 LATIN AMERICA: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 61 MIDDLE EAST: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 62 GCC COUNTRIES: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 63 BIOBURDEN TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 64 NORTH AMERICA: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 65 EUROPE: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 66 ASIA PACIFIC: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 67 LATIN AMERICA: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 68 MIDDLE EAST: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 69 GCC COUNTRIES: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 70 OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 71 NORTH AMERICA: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 72 EUROPE: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 73 ASIA PACIFIC: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 74 LATIN AMERICA: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 75 MIDDLE EAST: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 76 GCC COUNTRIES: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 77 BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 78 NORTH AMERICA: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 79 EUROPE: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 80 ASIA PACIFIC: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 81 LATIN AMERICA: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 82 MIDDLE EAST: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 83 GCC COUNTRIES: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 84 BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 85 NORTH AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 86 EUROPE: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 87 ASIA PACIFIC: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 88 LATIN AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 89 MIDDLE EAST: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 90 GCC COUNTRIES: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 91 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 92 RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 93 NORTH AMERICA: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 94 EUROPE: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 95 ASIA PACIFIC: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 96 LATIN AMERICA: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 97 MIDDLE EAST: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 98 GCC COUNTRIES: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 99 MYCOPLASMA TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 100 NORTH AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 101 EUROPE: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 102 ASIA PACIFIC: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 103 LATIN AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 104 MIDDLE EAST: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 105 GCC COUNTRIES: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 106 STERILITY TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 107 NORTH AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 108 EUROPE: STERILITY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 109 ASIA PACIFIC: STERILITY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 110 LATIN AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 111 MIDDLE EAST: STERILITY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 112 GCC COUNTRIES: STERILITY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 113 ENDOTOXIN TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 114 NORTH AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 115 EUROPE: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 116 ASIA PACIFIC: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 117 LATIN AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 118 MIDDLE EAST: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 119 GCC COUNTRIES: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 120 VIRUS SAFETY TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 121 NORTH AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 122 EUROPE: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 123 ASIA PACIFIC: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 124 LATIN AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 125 MIDDLE EAST: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 126 GCC COUNTRIES: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 127 BIOBURDEN TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 128 NORTH AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 129 EUROPE: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 130 ASIA PACIFIC: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 131 LATIN AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 132 MIDDLE EAST: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 133 GCC COUNTRIES: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 134 OTHER BIOLOGICS SAFETY TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 135 NORTH AMERICA: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 136 EUROPE: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 137 ASIA PACIFIC: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 138 LATIN AMERICA: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 139 MIDDLE EAST: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 140 GCC COUNTRIES: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 141 BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 142 BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
- TABLE 143 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 144 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 145 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 146 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 147 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
- TABLE 148 GCC: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 149 BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
- TABLE 150 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 151 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 152 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 153 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 154 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
- TABLE 155 GCC: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 156 BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
- TABLE 157 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 158 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 159 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 160 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 161 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
- TABLE 162 GCC: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 163 BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
- TABLE 164 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 165 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 166 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 167 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 168 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
- TABLE 169 GCC: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 170 BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
- TABLE 171 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 172 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 173 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 174 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 175 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
- TABLE 176 GCC: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 177 BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 178 BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
- TABLE 179 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 180 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 181 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 182 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 183 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
- TABLE 184 GCC: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 185 BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY REGION, 2022–2029 (USD MILLION)
- TABLE 186 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 187 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 188 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 189 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 190 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY REGION, 2022–2029 (USD MILLION)
- TABLE 191 GCC: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 192 BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
- TABLE 193 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 194 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 195 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 196 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 197 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
- TABLE 198 GCC: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 199 BIOLOGICS SAFETY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 200 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 201 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 202 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 203 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 204 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 205 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 206 US: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 207 US: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 208 US: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 209 US: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 210 US: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 211 CANADA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 212 CANADA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 213 CANADA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 214 CANADA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 215 CANADA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 216 EUROPE: INDICATIVE LIST OF APPROVED MONOCLONAL ANTIBODY TREATMENTS
- TABLE 217 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY/REGION, 2022–2029 (USD MILLION)
- TABLE 218 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 219 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 220 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 221 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 222 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 223 GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 224 GERMANY: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 225 GERMANY: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 226 GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 227 GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 228 UK: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 229 UK: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 230 UK: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 231 UK: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 232 UK: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 233 FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 234 FRANCE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 235 FRANCE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 236 FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 237 FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 238 ITALY: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 239 ITALY: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 240 ITALY: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 241 ITALY: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 242 ITALY: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 243 SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 244 SPAIN: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 245 SPAIN: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 246 SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 247 SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 248 REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 249 REST OF EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 250 REST OF EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 251 REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 252 REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 253 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 254 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 255 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 256 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 257 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 258 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 259 CHINA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 260 CHINA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 261 CHINA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 262 CHINA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 263 CHINA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 264 JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 265 JAPAN: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 266 JAPAN: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 267 JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 268 JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 269 INDIA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 270 INDIA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 271 INDIA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 272 INDIA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 273 INDIA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 274 SOUTH KOREA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 275 SOUTH KOREA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 276 SOUTH KOREA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 277 SOUTH KOREA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 278 SOUTH KOREA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 279 AUSTRALIA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 280 AUSTRALIA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 281 AUSTRALIA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 282 AUSTRALIA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 283 AUSTRALIA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 284 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 285 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 286 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 287 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 288 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 289 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY/REGION, 2022–2029 (USD MILLION)
- TABLE 290 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 291 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 292 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 293 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 294 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 295 BRAZIL: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 296 BRAZIL: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 297 BRAZIL: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 298 BRAZIL: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 299 BRAZIL: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 300 MEXICO: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 301 MEXICO: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 302 MEXICO: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 303 MEXICO: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 304 MEXICO: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 305 REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 306 REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 307 REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 308 REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 309 REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 310 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 311 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 312 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 313 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 314 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 315 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 316 GCC COUNTRIES: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 317 GCC COUNTRIES: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 318 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 319 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 320 GCC COUNTRIES: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 321 GCC COUNTRIES: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 322 SAUDI ARABIA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 323 SAUDI ARABIA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 324 SAUDI ARABIA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 325 SAUDI ARABIA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 326 SAUDI ARABIA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 327 UAE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 328 UAE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 329 UAE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 330 UAE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 331 UAE: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 332 REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 333 REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 334 REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 335 REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 336 REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 337 REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 338 REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 339 REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 340 REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 341 REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 342 AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
- TABLE 343 AFRICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
- TABLE 344 AFRICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
- TABLE 345 AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 346 AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 347 BIOLOGICS SAFETY TESTING MARKET: STRATEGIES ADOPTED
- TABLE 348 BIOLOGICS SAFETY TESTING MARKET: DEGREE OF COMPETITION
- TABLE 349 BIOLOGICS SAFETY TESTING MARKET: PRODUCT AND SERVICE FOOTPRINT
- TABLE 350 BIOLOGICS SAFETY TESTING MARKET: REGIONAL FOOTPRINT
- TABLE 351 BIOLOGICS SAFETY TESTING MARKET: TEST TYPE FOOTPRINT
- TABLE 352 BIOLOGICS SAFETY TESTING MARKET: APPLICATION FOOTPRINT
- TABLE 353 BIOLOGICS SAFETY TESTING MARKET: DETAILED LIST OF KEY START-UPS/SMES
- TABLE 354 BIOLOGICS SAFETY TESTING MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES
- TABLE 355 BIOLOGICS SAFETY TESTING MARKET: PRODUCT LAUNCHES, JANUARY 2021–JANUARY 2024
- TABLE 356 BIOLOGICS SAFETY TESTING MARKET: DEALS, JANUARY 2021–JANUARY 2024
- TABLE 357 BIOLOGICS SAFETY TESTING MARKET: EXPANSIONS, JANUARY 2021–JANUARY 2024
- TABLE 358 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
- TABLE 359 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 360 THERMO FISHER SCIENTIFIC INC.: DEALS
- TABLE 361 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS
- TABLE 362 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
- TABLE 363 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 364 CHARLES RIVER LABORATORIES: PRODUCT LAUNCHES
- TABLE 365 CHARLES RIVER LABORATORIES: DEALS
- TABLE 366 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
- TABLE 367 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 368 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS
- TABLE 369 LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS
- TABLE 370 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
- TABLE 371 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 372 MERCK KGAA: COMPANY OVERVIEW
- TABLE 373 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 374 MERCK KGAA: EXPANSIONS
- TABLE 375 SARTORIUS AG: COMPANY OVERVIEW
- TABLE 376 SARTORIUS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 377 LONZA: COMPANY OVERVIEW
- TABLE 378 LONZA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 379 LONZA: PRODUCT LAUNCHES
- TABLE 380 LONZA: DEALS
- TABLE 381 LONZA: EXPANSIONS
- TABLE 382 FUJIFILM CORPORATION: COMPANY OVERVIEW
- TABLE 383 FUJIFILM CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 384 FUJIFILM CORPORATION: PRODUCT LAUNCHES
- TABLE 385 FUJIFILM CORPORATION: DEALS
- TABLE 386 FUJIFILM CORPORATION: EXPANSIONS
- TABLE 387 BIOMÉRIEUX: COMPANY OVERVIEW
- TABLE 388 BIOMÉRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 389 MARAVAI LIFESCIENCES: COMPANY OVERVIEW
- TABLE 390 MARAVAI LIFESCIENCES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 391 MARAVAI LIFESCIENCES: PRODUCT LAUNCHES
- TABLE 392 MARAVAI LIFESCIENCES: DEALS
- TABLE 393 WUXI APPTEC: COMPANY OVERVIEW
- TABLE 394 WUXI APPTEC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 395 WUXI APPTEC: DEALS
- TABLE 396 WUXI APPTEC: EXPANSIONS
- TABLE 397 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY OVERVIEW
- TABLE 398 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 399 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: EXPANSIONS
- TABLE 400 SOTERA HEALTH: COMPANY OVERVIEW
- TABLE 401 SOTERA HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 402 SOTERA HEALTH: DEALS
- TABLE 403 SOTERA HEALTH: EXPANSIONS
- TABLE 404 SAMSUNG BIOLOGICS: COMPANY OVERVIEW
- TABLE 405 SAMSUNG BIOLOGICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 406 SAMSUNG BIOLOGICS: DEALS
- TABLE 407 SAMSUNG BIOLOGICS: EXPANSIONS
- TABLE 408 GENSCRIPT: COMPANY OVERVIEW
- TABLE 409 GENSCRIPT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 410 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
- TABLE 411 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 412 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
- TABLE 413 SYNGENE INTERNATIONAL LIMITED: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 414 SYNGENE INTERNATIONAL LIMITED: DEALS
- TABLE 415 SYNGENE INTERNATIONAL LIMITED: EXPANSIONS
- TABLE 416 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
- TABLE 417 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 418 EUROFINS SCIENTIFIC: DEALS
- TABLE 419 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
- TABLE 420 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 421 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES
- TABLE 422 BIO-RAD LABORATORIES, INC.: DEALS
- TABLE 423 QIAGEN: COMPANY OVERVIEW
- TABLE 424 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 425 QIAGEN: PRODUCT LAUNCHES
- TABLE 426 PROMEGA CORPORATION: COMPANY OVERVIEW
- TABLE 427 CATALENT, INC.: COMPANY OVERVIEW
- TABLE 428 ASSOCIATES OF CAPE COD, INC.: COMPANY OVERVIEW
- TABLE 429 CLEAN BIOLOGICS: COMPANY OVERVIEW
- TABLE 430 PATHOQUEST: COMPANY OVERVIEW
- TABLE 431 PACIFIC BIOLABS: COMPANY OVERVIEW
- TABLE 432 ARL BIO PHARMA, INC.: COMPANY OVERVIEW
- TABLE 433 FRONTAGE LABS: COMPANY OVERVIEW
- TABLE 434 CREATIVE BIOGENE: COMPANY OVERVIEW
- TABLE 435 ADVAXIA BIOLOGICS: COMPANY OVERVIEW
- FIGURE 1 RESEARCH DESIGN
- FIGURE 2 BIOLOGICS SAFETY TESTING MARKET: BREAKDOWN OF PRIMARIES
- FIGURE 3 BIOLOGICS SAFETY TESTING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
- FIGURE 4 BIOLOGICS SAFETY TESTING MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
- FIGURE 5 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC. (2023)
- FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
- FIGURE 7 SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
- FIGURE 8 BIOLOGICS SAFETY TESTING MARKET: CAGR PROJECTIONS
- FIGURE 9 DATA TRIANGULATION METHODOLOGY
- FIGURE 10 BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
- FIGURE 11 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2024 VS. 2029 (USD MILLION)
- FIGURE 12 BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
- FIGURE 13 BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
- FIGURE 14 GEOGRAPHICAL SNAPSHOT OF BIOLOGICS SAFETY TESTING MARKET
- FIGURE 15 INCREASING DEVELOPMENT OF MONOCLONAL ANTIBODIES AND BIOSIMILARS TO SUPPORT MARKET GROWTH
- FIGURE 16 SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2023
- FIGURE 17 MONOCLONAL ANTIBODIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
- FIGURE 18 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT DOMINATED MARKET IN 2023
- FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
- FIGURE 20 BIOLOGICS SAFETY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
- FIGURE 21 NUMBER OF ANTIBODY THERAPEUTICS GRANTED A FIRST APPROVAL IN US OR EU, 2012–2023
- FIGURE 22 WORLDWIDE TOTAL PHARMACEUTICAL R&D SPEND, 2014–2028
- FIGURE 23 BIOLOGICS SAFETY TESTING MARKET: SUPPLY CHAIN ANALYSIS
- FIGURE 24 BIOLOGICS SAFETY TESTING MARKET: VALUE CHAIN ANALYSIS
- FIGURE 25 BIOLOGICS SAFETY TESTING MARKET: ECOSYSTEM ANALYSIS
- FIGURE 26 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
- FIGURE 27 TOTAL NUMBER OF PATENTS GRANTED, 2014–2024
- FIGURE 28 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2024
- FIGURE 29 BIOLOGICS SAFETY TESTING MARKET: PORTER’S FIVE ANALYSIS
- FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOLOGICS SAFETY TESTING PRODUCTS
- FIGURE 31 KEY BUYING CRITERIA FOR END USERS
- FIGURE 32 GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028 (USD BILLION)
- FIGURE 33 NUMBER OF BIOSIMILARS APPROVED ANNUALLY BY US FDA, 2015 TO 2023
- FIGURE 34 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET SNAPSHOT
- FIGURE 35 TOTAL US NIH BIOTECHNOLOGY FUNDING, FY 2013 TO FY 2024
- FIGURE 36 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET SNAPSHOT
- FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS (2019–2023)
- FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
- FIGURE 39 BIOLOGICS SAFETY TESTING MARKET: BRAND/PRODUCT COMPARISON
- FIGURE 40 BIOLOGICS SAFETY TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
- FIGURE 41 BIOLOGICS SAFETY TESTING MARKET: OVERALL FOOTPRINT
- FIGURE 42 BIOLOGICS SAFETY TESTING MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
- FIGURE 43 EV/EBITDA OF KEY VENDORS
- FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
- FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
- FIGURE 46 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
- FIGURE 47 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
- FIGURE 48 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
- FIGURE 49 MERCK KGAA: COMPANY SNAPSHOT
- FIGURE 50 SARTORIUS AG: COMPANY SNAPSHOT
- FIGURE 51 LONZA: COMPANY SNAPSHOT
- FIGURE 52 FUJIFILM CORPORATION: COMPANY SNAPSHOT
- FIGURE 53 BIOMÉRIEUX: COMPANY SNAPSHOT
- FIGURE 54 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT
- FIGURE 55 WUXI APPTEC: COMPANY SNAPSHOT
- FIGURE 56 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY SNAPSHOT
- FIGURE 57 SOTERA HEALTH: COMPANY SNAPSHOT
- FIGURE 58 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
- FIGURE 59 GENSCRIPT: COMPANY SNAPSHOT
- FIGURE 60 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
- FIGURE 61 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT
- FIGURE 62 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
- FIGURE 63 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
- FIGURE 64 QIAGEN: COMPANY SNAPSHOT
Methodology
This study involved four major activities in estimating the current size of the biologics safety testing market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the US Food and Drug Administration (FDA), World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), News Articles, Press Releases. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global biologics safety testing market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the biologics safety testing market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
The biological safety testing market comprises the products and services used to assess the safety, purity, potency, and quality of biologically derived products across their development, manufacturing, and release stages.
Key Stakeholders
- Biologics safety testing products and services companies
- National and regional research boards and organizations
- Research & development companies
- Clinical research organizations (CROs)
- Biotechnology companies
- Research laboratories & academic institutes
- Market research & consulting firms
- Regulatory bodies
Report Objectives
- To define, describe, and forecast the biologics safety testing market by offering, test type, product application, service application, product end user, service end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biologics safety testing market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe biologics safety testing market, by country
- Further breakdown of the Rest of Asia Pacific biologics safety testing market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Biologics Safety Testing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
Growth opportunities and latent adjacency in Biologics Safety Testing Market
Biocompatibility
Nov, 2020
Fantastic piece of content. Thank you for sharing this..